

1 **TITLE**

2 Jointly leveraging spatial transcriptomics and deep learning models for pathology image
3 annotation improves cell type identification over either approach alone.

4

5 **AUTHORS AND AFFILIATIONS**

6 Asif Zubair¹, Richard H. Chapple¹, Sivaraman Natarajan¹, William C. Wright¹, Min Pan¹,
7 Hyeong-Min Lee¹, Heather Tillman², John Easton¹, Paul Geeleher^{1, #}.

8

9 ¹ Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
10 38105, USA

11 ² Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

12 # Correspondence: paul.geeleher@stjude.org

13

14 **ABSTRACT** (Approx. 150 words)

15 The disorganization of cell types within tissues underlies many human diseases and has been
16 studied for over a century using the conventional tools of pathology, including tissue-marking
17 dyes such as the H&E stain. Recently, spatial transcriptomics technologies were developed that
18 can measure spatially resolved gene expression directly in pathology-stained tissues sections,
19 revealing cell types and their dysfunction in unprecedented detail. In parallel, artificial
20 intelligence (AI) has approached pathologist-level performance in computationally annotating
21 H&E images of tissue sections. However, spatial transcriptomics technologies are limited in their
22 ability to separate transcriptionally similar cell types and AI-based pathology has performed less
23 impressively outside their training datasets. Here, we describe a methodology that can
24 computationally integrate AI-annotated pathology images with spatial transcriptomics data to
25 markedly improve inferences of tissue cell type composition made over either class of data
26 alone. We show that this methodology can identify regions of clinically relevant tumor immune

27 cell infiltration, which is predictive of response to immunotherapy and was missed by an initial
28 pathologist's manual annotation. Thus, combining spatial transcriptomics and AI-based image
29 annotation has the potential to exceed pathologist-level performance in clinical diagnostic
30 applications and to improve the many applications of spatial transcriptomics that rely on
31 accurate cell type annotations.

32

33 **BACKGROUND**

34 The traditional tools of histopathology, such as tissue-marking dyes like the hematoxylin and
35 eosin (H&E) stain, remain the primary tool used to study the disorganization and dysfunction of
36 cells within diseased tissue, representing a principal diagnostic tool in medicine. Although these
37 tools are very widely applied, they are limited by their reliance on cell morphology¹. In the last
38 five years, sequencing-based spatial transcriptomics technologies²⁻⁶ have emerged as a
39 powerful tool to measure spatially resolved genome-wide gene expression directly within
40 pathology-stained tissue sections, offering the potential to interrogate diseased tissue biology in
41 unprecedented detail^{7,8}. Novel computational methods have already begun to address several
42 analytical challenges posed by these new data, with specific tools developed to identify spatially
43 varying genes^{9,10}, spatial gene expression patterns^{11,12}, and cell-cell interactions^{13,14}. However,
44 the most fundamental problem posed by spatial transcriptomics data—upon which almost all
45 other applications of the data depend—is that of identifying the location and abundance of
46 different cell types (herein referred to as “cell type decomposition”). Several methods have
47 already been developed for this task and all function by leveraging the expression of a set of cell
48 type-specific marker genes to infer the abundance of each cell type at each slide region¹⁵⁻¹⁸.

49 Notably, while mRNA is typically captured from one side of a permeabilized tissue section,
50 sequencing-based spatial transcriptomics technologies also allow images of the opposite side of
51 the tissue section to be obtained (e.g. H&E or immunohistochemical stains). Recent advances

52 in artificial intelligence, specifically deep convolutional neural networks, have profoundly
53 improved our ability to computationally extract meaningful information from these types of
54 stained tissue images¹⁹. For example, it was recently shown that deep learning algorithms
55 applied to H&E-stained pathology slides from The Cancer Genome Atlas (TCGA) could identify
56 diagnostically informative features of tumors, including clinically relevant estimates of cell-type
57 composition, chromosomal ploidy and signaling pathway activity^{20,21}.

58 However, deep learning models and spatial transcriptomics platforms each have limitations and
59 neither technology alone has displaced conventional pathology techniques. For example,
60 methods for cell type decomposition in spatial transcriptomics data will always struggle to
61 differentiate between cell types that are transcriptionally similar due to statistical
62 multicollinearity²² and deep learning-based models for pathology have often failed to
63 recapitulate their expected performance when deployed on out-of-test-set data in real-world
64 settings^{23,24}.

65 Here, we present a conceptually novel computational methodology termed Guiding-Image
66 Spatial Transcriptomics (GIST). This method improves cell type decomposition in spatial
67 transcriptomics data by jointly leveraging gene expression data obtained from the spatial
68 transcriptomics platform with image-derived information from the same tissue section, for
69 example, the output of deep learning models applied to images of histopathology stains. We
70 applied this computational tool to integrate spatial transcriptomics data with deep learning-
71 derived cell type annotations in breast cancer pathology slides where we identified
72 prognostically relevant immune cell infiltration that was missed by an initial pathologist's manual
73 annotation. The methodology presented is generalizable to any sequencing-based spatial
74 transcriptomics platform where informative image-derived cell-type compositional estimates can
75 be obtained. Thus, combining spatial transcriptomics and paired pathology images has potential


- 76 applications in clinical diagnostics and can also improve all analytical applications of spatial
77 transcriptomics data that rely on the correct annotation of cell types.

78 **RESULTS**

79 **Guiding-Image Spatial Transcriptomics (GIST) jointly leverages spatial transcriptomics**
 80 **and paired tissue images to improve cell type decomposition.**

81 GIST attempts to improve cell type decomposition in spatial transcriptomics data by leveraging
 82 prior estimates of cell type composition from paired pathology images. The method relies on
 83 Bayesian probabilistic modeling, a statistical approach that naturally lends itself to integrating
 84 multiple sources of information, jointly leveraging spatial transcriptomics and imaging
 85 information to improve cell type decomposition estimates over either approach applied alone.
 86 Intuitively, the approach uses the imaging data to provide an initial “suggestion” as to the cell
 87 types in a particular region of the spatial transcriptomics slide, but this suggestion can be
 88 overcome if outweighed by the evidence from the transcriptomic data (schematic representation
 89 in Fig. 1a, model formation in Fig. 1b; see Methods for further technical details).

90



91

92 **Figure 1: Overview of Guiding-Image Spatial Transcriptomics (GIST) methodology.**

93 a) Schematic representation of GIST. The schematic shows a hypothetical tissue section, where we
 94 wish to identify the location of a hypothetical cell type (colored orange); this could represent, for

95 example, immune cell infiltration in a tumor. Estimates of this cell type's proportions from a deep
96 learning model applied to an H&E stain image (left) are used to optimize the estimates derived
97 from the spatial transcriptomics data (right), yielding improved estimates over what could be
98 achieved from either approach alone (bottom right).

99 b) Mathematical notation describing the GIST model: We assume that the spatial transcriptomics
100 data $\mathbf{Y}_{m \times n}$ can be approximately factorized as a cell type signature matrix $\mathbf{W}_{m \times p}$ and a matrix of
101 cell type compositional estimates $\mathbf{H}_{p \times n}$ (eqn. (1)). We propose estimating cell type composition \mathbf{H}
102 using the model in eqn. (2-9). A single-cell RNA-seq dataset from the same tissue type is
103 represented by Ψ . Each element of \mathbf{W} is estimated from Ψ using a negative binomial distribution
104 (with overdispersion parameter $\phi_{i,k}$) estimated for each gene i , in each cell type k , from the
105 expression in each single-cell l . Eqn. (5) shows the model constraints. Eqn. (6-9) show the priors,
106 denoted by π . Other parameters are assigned weakly informative priors. The key informative prior
107 is shown in eqn. (9), where the image-derived prior estimate of cell type composition for a cell
108 type of interest, contained in row a of \mathbf{H} , is specified as a beta distribution. For each tissue region
109 (e.g. unique barcoded spot), this beta distribution is parameterized by its mean, τ_j , specifying the
110 prior cell type composition estimate from the image, and the hyperparameter λ , a scalar that
111 determines how much weight to place on the image data and how much to place on the
112 transcriptomic data. Notes: Superscript notation (e.g. $\mathbf{H}^{(i)}$) denotes the columns of a matrix.
113 Vectors are shown using boldface and matrices bold capital letters. All equations herein assume
114 m genes (indexed by i), n tissue regions (e.g. slide mRNA capture spots, indexed by j), p cell
115 types (indexed by k).


116

117 **A Bayesian probabilistic model for cell type decomposition performs competitively when**
118 **compared to existing methods in simulations when no paired image information is**
119 **leveraged.**

120 Existing methods for cell type decomposition in spatial transcriptomics data are related to
121 previous models for bulk gene expression deconvolution and can be broadly conceptualized as
122 a matrix decomposition, where some reference basis matrix of expression data from purified
123 cells \mathbf{W} (e.g. derived from single-cell RNA-seq) is used to estimate the proportion of each cell
124 type \mathbf{H} in the bulk mixture \mathbf{Y} (Fig. 2a for schematic representation). At subcellular resolution, the
125 \mathbf{H} matrix can be thought of as probability estimates, rather than proportion estimates¹⁶, although
126 for simplicity we use the term "proportion" throughout this manuscript.

127 The statistical model underlying GIST is related to these existing approaches but includes the
128 ability to leverage prior information derived from paired tissue images. Thus, we were first

129 interested in assessing whether our model performed competitively when compared to existing
130 approaches in the absence of prior information derived from images (*henceforth referred to as*
131 *the “GIST base-model”*). To test this, we first developed two complementary unbiased
132 benchmarking simulations, one based on the existing tool Splatter²⁵ and one based on a
133 published benchmarking dataset²⁶, which evaluates methods on a simulated mixture of immune
134 cell types from a real single-cell RNA-seq dataset. We compared the GIST base-model to two
135 methods originally designed for bulk gene expression data (CIBERSORT²⁷, DeconRNASeq²⁸), a
136 method tailored specifically for spatial transcriptomics data (Stereoscope¹⁸), and linear
137 regression (the simplest conceivable model.) Based on the mean absolute error (*MAE*),
138 CIBERSORT performed slightly better on the Splatter simulations (Fig. 2b, Supplementary
139 Figure 1, Supplementary Table S1; $MAE = 6.8 \times 10^{-2}$ for CIBERSORT and 7.4×10^{-2} for the
140 GIST base-model), while the GIST base-model performed best on the other benchmarking
141 dataset (Fig. 2c, Supplementary Figure 2, Supplementary Table S2; $MAE = 0.09$ for
142 CIBERSORT and 0.06 for the GIST base-model). However, given the conceptual similarity of
143 the underlying models, it is not surprising that none of these existing methods produce markedly
144 dissimilar results in either simulation, suggesting that, rather than further model tweaking and
145 optimization, a new conceptual advance may be necessary to achieve meaningful progress on
146 the cell type decomposition problem.



147

148 **Figure 2: A Bayesian probabilistic model performs similarly to existing cell type decomposition**
 149 **methods when no prior information is available.**

- 150 a) Schematic representation of the cell type decomposition problem posed as a matrix
 151 decomposition. Spatial transcriptomics expression data is arranged in an m genes-
 152 mRNA-capture-spots matrix Y . This matrix is decomposed into a basis matrix W and a matrix H
 153 that contains the proportion of each of p cell types on each spot or (at subcellular resolution)
 154 the probability that a spot matches a cell type (shown for three hypothetical cell types A, B, and C).
 155 The basis matrix W is typically known and can be derived for example from single-cell RNA-seq
 156 data from the same or similar tissue. Given this, all existing cell type decomposition algorithms,
 157 be they designed specifically for spatial transcriptomics data or not, aim to estimate H .
 158 b) Boxplot showing the results of five cell type decomposition methods on simulated mixture gene
 159 expression data, for a mixture of 6 cell types, generated using the tool Splatter (see Methods).
 160 Points have been colored by the simulated cell type and the y-axis shows the deviation from
 161 ground truth, quantified by the difference between the estimated cell type proportions in a sample
 162 and the true proportion used as ground truth for the simulation. The Mean Absolute Error (MAE),
 163 summarizing the overall performance of each method is as follows (lower values imply better
 164 performance): Linear regression = 0.13, CIBERSORT = 6.8×10^{-2} , DeconRNAseq = 0.11,
 165 Stereoscope = 0.15, GIST base-model = 7.4×10^{-2} .
 166 c) Similar to (b) but based on the simulated dataset obtained from the benchmarking procedure
 167 outlined in Strum *et al.*²⁶. Points have been colored by the immune cell type and the y-axis shows
 168 the deviation from ground truth, quantified by the difference between the estimated cell type
 169 proportions in a sample and the true proportion used as ground truth for the simulation. The Mean
 170 Absolute Error (MAE), summarizing the overall performance of each method is as follows (lower

171 values imply better performance): Linear regression = 0.14, CIBERSORT = 0.09, DeconRNAseq
172 = 0.1, GIST base-model = 6.4×10^{-2} . Note Stereoscope is not included in this second set of
173 simulations as it was not possible to pass the CIBERSORT LM22 signature matrix, which is used
174 as the cell-type reference in this simulation, to Stereoscope (see Methods).

175 In all boxplots, the center line represents the median, bound of box is upper and lower quartiles
176 and the whiskers are $1.5 \times$ the interquartile range.

177

178 **The GIST base-model performs competitively on spatial transcriptomics data obtained**
179 **from mouse brain sections when cell type specific immunofluorescence markers are**
180 **treated as a ground truth.**

181 We were next interested in comparing the performance of the GIST base-model to other
182 methods using real spatial transcriptomics data. To do this, we leveraged a publicly available
183 dataset (see Data Availability), which measured gene expression in the mouse brain using the
184 10x Genomics Visium spatial transcriptomics platform, and where immunofluorescence (IF)
185 staining was performed on the reverse side of the tissue section. These IF stains were
186 conducted for two proteins, RBFOX3 and GFAP, which are protein markers unique to neurons
187 and glia respectively (Fig. 3a). We calculated the average pixel intensity of each of these two
188 markers in all image pixels overlapping each spatially barcoded mRNA capture spot on the
189 Visium slide (Fig. 3b; see Methods), then we used these spot-level intensity estimates to
190 represent an independent ground-truth approximating the abundance of neurons and glia in
191 regions of the slide overlapping each of the Visium array's 4,992 spots.

192 Next, using the GIST base-model, we estimated the cell type composition on each spot from the
193 spatial transcriptomics data by leveraging a single-cell RNA-seq dataset that was available from
194 a similar region of a mouse brain, allowing us to estimate the abundance of glial and neuronal
195 cell types from the spatial transcriptomics expression data alone (Fig. 3c). We compared the
196 results obtained from the GIST base-model to popular spatial transcriptomics cell type
197 decomposition methods Spotlight¹⁵, RCTD¹⁶, Stereoscope¹⁸, and Cell2location²⁹, treating the IF-

198 derived estimates of neurons and glia at each spot as ground truth. Consistent with our
199 simulations, the GIST base-model, RCTD, Cell2location, and Spotlight all performed quite
200 similarly in these benchmarks on real data; however, we note that the GIST base-model had
201 slightly better performance than the other methods, achieving Spearman's rank correlations of
202 0.49 and 0.77, compared to 0.33 and 0.77 for RCTD (the second best performing method), for
203 the glial and neuronal comparisons respectively (Fig. 3d; $P < 2.2 \times 10^{-16}$ from Spearman's
204 correlation against IF-derived ground truth for all five methods; Supplementary Figures 3-7).
205 Overall, these results suggest that the GIST base-model performs competitively when
206 compared to existing methods for cell type decomposition in real spatial transcriptomics data.

207


208 **Incorporating image-derived prior information from matched immunofluorescence stains**
209 **improves cell type decomposition in spatial transcriptomics data generated from a**
210 **mouse brain section.**

211 Even though our GIST base-model performed well compared to existing methods, the results
212 above also showed that the best-performing methods were not markedly different and fall well
213 short of an optimal performance when compared to the IF-derived ground truth. Thus, we next
214 hypothesized that it should be possible to markedly improve our performance by leveraging our
215 model's Bayesian implementation and supplying the model with informative image-derived prior
216 information (*henceforth referred to as the "GIST model"*). We reasoned that we could first
217 demonstrate this principle on this mouse brain dataset, leveraging the IF-derived estimates of
218 cell type abundance. However, IF-derived pixel intensity estimates do not represent proportions
219 on a 0-1 scale and thus it is not obvious how this information could be leveraged as prior
220 estimates of cell type composition in the GIST model. To solve this problem, we first normalized
221 the IF-derived estimates by mapping them onto the quantiles of the spatial transcriptomics-
222 derived cell type proportion estimates, generated by an initial round of model fitting using the

223 GIST base-model (Fig. 3e-g; see Methods). We then refit our GIST model, incorporating this
224 prior knowledge derived from the RBFOX3 IF data, providing “suggestions” of the abundance of
225 neuronal cell types over each spatial transcriptomics spot. We specified these priors using a
226 beta distribution applied to the appropriate group of model parameters corresponding to
227 neuronal cell type estimates. The beta distribution was parameterized by its mean (τ ; the point
228 estimate of the normalized cell type proportion estimate from the IF image) and the total-count
229 parameter (λ ; the strength of the prior, corresponding to the weight placed on the IF image)—
230 any beta distribution is naturally constrained to a 0-1 scale, meaning it is appropriate for
231 specifying image-derived prior estimates of cell type composition. The key modeling question is
232 then determining how much weight to place on these image-derived priors and how much to
233 place on the spatial transcriptomics data itself. This must be determined by tuning the
234 hyperparameter λ , where selecting a value that is too small will mean there is little to no
235 influence of the image-derived cell type information on the model’s output but selecting a value
236 that is too large will overfit the model to the image and degrade performance on unseen test
237 data.

238 We chose this hyperparameter λ by observing how the estimates of glial cell type composition
239 compared to IF-derived glial-cell ground-truth (GFAP stain) when fitting the model with ever-
240 increasing values of λ for the IF-derived neuronal cell type prior (RBFOX3 stain), only placing
241 priors on the neuronal cell types. As expected, when increasing the value of λ and placing more
242 weight on the image-derived prior for neuronal cells, the model’s output progressively more
243 closely matched these IF-derived estimates for the neuronal cell types (Fig. 3h). However, as
244 we continued to increase λ , placing more and more weight on the image-derived estimates of
245 neuronal cells, we eventually observed a precipitous drop-off in the model’s performance, as
246 measured by the agreement between the glial cell type estimates from the GIST model and the
247 IF-derived ground truth from the GFAP glial marker protein (Fig. 3h). This drop-off begins at $\lambda =$

248 50, suggesting that beyond this point the model has been overfitted, providing us a reasonable
249 value of λ for image-derived priors. This value of λ concentrates most of the prior probability
250 mass within approximately $\pm 10\%$ of the mean. Notably, at this λ value, the Spearman's rank
251 correlation between the model-derived neuronal cell type estimates and the IF-derived ground
252 truth increased from 0.7 to 0.85, substantially better than any method that does not leverage the
253 images and approaching an optimal performance (Figs. 3i and 3j). Overall, these results support
254 the notion that applying informative prior information, derived from matched images has the
255 potential to improve the performance of cell type decomposition in spatial transcriptomics data
256 and provides a reasonable initial estimate of the key hyperparameter λ to now be applied to out-
257 of-batch test datasets.



258

259 **Figure 3: Incorporating image-derived prior information from matched immunofluorescence stains**
 260 **in mouse brain spatial transcriptomics data.**

- 261 a) Raw immunofluorescence image of the mouse brain tissue section showing the glial (GFAP) and
 262 neuronal (RBFOX3) cell markers.
- 263 b) Spatial distribution of raw IF intensity values for GFAP (glial) and RBFOX3 (neuronal) when
 264 fluorescence intensity has been averaged over pixels corresponding to each spatial
 265 transcriptomics spot's location. Intensity values were rescaled from 0 to 1.
- 266 c) Spatial distribution of glial and neuronal proportions estimated from the spatial transcriptomics
 267 gene expression data using the GIST base-model.
- 268 d) Bar plot showing Spearman's correlation between IF-derived ground truth cell type proportions
 269 and cell type proportions estimated from five different gene expression-based spatial

- 270 transcriptomics cell type decomposition methods (Stereoscope, cell2location, SPOTlight, RCTD,
271 and the GIST base-model).
- 272 e) Quantile-quantile plot (QQ plot) of image-based IF-derived values for total glial and neuronal
273 content for each spot (y-axis) versus values obtained for total glial and neuronal content from the
274 spatial transcriptomics gene expression data only using the GIST base-model (x-axis).
- 275 f) Same as in (d) except that this QQ plot is generated after post-mapping normalization where the
276 distribution of cell type compositional estimates from the IF images were mapped onto the
277 distribution of cell type compositional estimates from the spatial transcriptomics gene expression
278 data generated using the GIST base-model.
- 279 g) Spatial distribution of IF intensity values for the glial and neuronal channel where the values have
280 now been mapped to a distribution estimated from the gene expression data using the GIST base-
281 model.
- 282 h) Line plot showing the change in GIST model performance as we increase the key hyperparameter
283 λ (x-axis). Performance is quantified by Spearman correlation with IF-derived ground truth (y-
284 axis) and is shown for both neuronal (green) and glial (blue) cell types. The RBFOX3 IF image-
285 derived prior is only applied to the neuronal cell type. A non-informative prior is applied to the
286 glial cell type. The vertical dashed red line indicates a stopping point ($\lambda = 50$) where performance
287 in the glial channel begins to deteriorate, indicating the model has been overfitted to the RBFOX3
288 IF data.
- 289 i) Scatter plots showing the cell type compositional estimates against IF-derived ground truth (x-
290 axis) in the mouse brain for glia (left) and neurons (right) derived from the spatial transcriptomics
291 gene expression data using the GIST base-model (y-axis) when no prior information is leveraged.
292 *P*-values from Spearman's correlation test.
- 293 j) Similar to (i) but showing the improved agreement with ground truth (x-axis) when the IF-derived
294 cell type compositional estimates are incorporated as prior information using the GIST model
295 with a λ hyperparameter value of 50 (y-axis). *P*-values from Spearman's correlation test.
- 296 Abbreviations: ST, Spatial Transcriptomics; IF: Immunofluorescence.

297


298 **Incorporating prior information derived from deep learning models applied to matched**
299 **H&E-stained images improves estimates of immune cell infiltration in breast cancer**
300 **spatial transcriptomics data.**

301 The results above provide a convincing proof-of-principle that it should be possible to improve
302 cell type decomposition in spatial transcriptomics data by leveraging matched images. However,
303 while IF stains can provide reliable markers of cell types, they are restricted to a small number
304 of proteins and are much less commonly collected than the H&E stain. Thus, we wondered
305 whether it would be possible to leverage image information derived from deep learning models
306 applied to H&E stains—the principal pathology stain that is collected as a part of almost all

307 sequencing-based spatial transcriptomics protocols. Deep learning models have already been
308 developed that can output numerous clinically relevant annotations from H&E-stained tissue
309 section images alone, which could theoretically be usefully propagated in the spatial
310 transcriptomics assay. These annotations include cell type composition, expression of signaling
311 pathways, chromosomal ploidy, and immune cell infiltration^{20,21,30}. To test whether such
312 information could be usefully exploited in spatial transcriptomics assays, we obtained 8
313 previously published spatial transcriptomics tissue slides, which had measured gene expression
314 in biologically independent breast cancer tumors. Critically, each of these tissue sections had
315 also been H&E stained (Fig. 4a, panel (a) in Supplementary Figures S8-S12), and regions of
316 immune cell infiltration had been annotated by a previous pathologist (Fig. 4b, panel (b) in
317 Supplementary Figure S8-S12), providing an independent ground truth against which to assess
318 our model predictions. Identifying immune cell infiltration has prognostic value³¹ and is predictive
319 of response to cancer immunotherapy³², hence represents a particularly interesting use case of
320 the GIST model.

321 Thus, we applied a previously published deep convolutional neural network³⁰, which had been
322 trained using images collected as part of TCGA to identify regions of tumor-infiltrating
323 lymphocytes from H&E stained tumor tissue sections. This yielded patches of deep learning-
324 derived predictions of immune cell infiltration across each of our breast cancer tumor tissue
325 sections (Fig. 4c, panel (c) in Supplementary Figures S8-S12), where gene expression had also
326 been measured using spatial transcriptomics. We then averaged these deep learning derived
327 predictions over the pixels overlapping each of the spatial transcriptomics mRNA capture spots,
328 yielding a deep-learning-derived per-spot estimate of immune cell composition in each tumor
329 (Fig. 4d, panel (d) in Supplementary Figures S8-S12, similar to the approach applied above for
330 IF data; see Methods). Initial immune cell proportions at each spot were then estimated using
331 the GIST base-model (Fig. 4e, panel (e) in Supplementary Figures S8-S12). We applied a

332 similar normalization approach as we described for the IF data, mapping the deep learning
333 derived estimates to the quantiles of the initial gene expression derived estimates, then applied
334 these deep-learning-derived immune cell compositional estimates as informative priors, again
335 specified as a beta distribution on the appropriate GIST model parameters. We used a λ value
336 of 50, which was derived from the previous independent mouse brain dataset, avoiding any
337 potential issues with overfitting to this new dataset (Fig. 3h). If the GIST model performs better
338 than the expression-only GIST base-model, the expectation is that we should identify more
339 immune cells in pathologist-annotated immune cell regions, but less in other regions of the
340 slides. Thus, we quantified model performance by the ratio of immune cells identified within the
341 pathologist's annotated regions of immune infiltration, compared to all other regions of the tissue
342 slide (this ratio is defined herein as Q (see Methods); note that regions of immune cells had
343 been identified by the pathologist in six of eight slides). When compared to the pathologist-
344 derived ground truth, the GIST model, leveraging deep learning-derived prior information,
345 performed better than the expression-only GIST base-model in four out of the six slides (Fig. 4f,
346 panel (f) in Supplementary Figures S8-S12). The performance increase over the GIST base-
347 model was particularly large for two slides (Fig. 4g, panel (g) in Supplementary Figures S8-S12;
348 increase in Q for GIST vs GIST base-model (defined herein as Δ) of 1.95 and 2.69, $P = 7.2 \times 10^{-3}$
349 and $P < 2.2 \times 10^{-16}$ for slides A1 and G1 respectively; empirical P -values were calculated by
350 permutation, see Methods). Visual inspection of the results revealed examples of clear regions
351 where leveraging the deep learning-derived prior information correctly decreased the estimates
352 of immune cell composition in regions where the pathologist marked an absence of immune
353 cells (Fig. 4h, black arrowhead, and Fig. 4i) and regions where estimates of immune cell
354 composition increased to match the pathologist (Fig. 4h, green arrowhead). Thus, leveraging
355 deep learning derived prior information has the potential to markedly improve cell type
356 decomposition in data generated from spatial transcriptomics technologies.



357

358 **Figure 4: Tissue image-derived cell type compositional estimates can be leveraged to improve**
 359 **estimates of immune cell infiltration in breast cancer tissue sections profiled using spatial**
 360 **transcriptomics.**

- 361 a) H&E stained tissue image obtained from the reverse side of the breast cancer spatial
 362 transcriptomics slide G1. Green outline shows regions containing ST spots annotated as
 363 containing immune cells by the pathologist.
 364 b) Pathologist annotation for slide G1 showing regions containing spatial transcriptomics spots that
 365 were labeled immune cell infiltrated (marked by dark-colored spots and green outlines).
 366 c) Output from the deep learning model for slide G1 overlaid on top of the breast cancer tissue
 367 section H&E image. The color scale indicates deep learning-derived predictions for the
 368 proportions of immune cells made on 50×50 micron patches of the tissue. Green boxes outline
 369 regions of pathologist's annotated immune spots.
 370 d) Slide G1 showing the patch level deep learning predictions converted to spot level predictions, so
 371 that they can be used as priors in the GIST model. Spot level predictions are a sum of patch level
 372 predictions weighted by their percent overlap with the spot. Boxes outline regions of
 373 pathologist's annotated immune spots.

- 374 e) Slide G1 showing the gene expression-derived immune cell proportions from the GIST base
375 model. Solid boxes indicate the regions of the pathologist's annotated immune spots. Green
376 indicates that the model reasonably identifies immune-infiltrated spots. Red indicates that the
377 immune spots were not captured by the model. The dashed black box indicates a region of
378 interest that likely is a false positive (see panels (h) and (i)).
- 379 f) Scatterplot showing the performance of the GIST model (y-axis) versus the performance of a
380 base-model based on only gene expression data (x-axis) for six pathologist-annotated spatial
381 transcriptomics slides. Performance is defined as the ratio of the median proportion of immune
382 cells in pathologist labeled immune cell slide spots, versus the median proportion of immune cells
383 in the other slide spots (Q , see Methods). Points are colored by slide ID. The red line is the
384 identity line (intercept of 0, slope of 1), and the distance between this line and each point (black
385 arrow) represents the observed test statistic Δ for that sample.
- 386 g) Histogram showing the empirical null distribution of ratio-based test statistic (Δ_{perm} , see
387 Methods) generated using a permutation procedure (x-axis). The test statistic is a measure of
388 improvement in model performance, versus the pathologist-annotated ground truth, when deep-
389 learning derived prior cell type annotations are incorporated. The observed test statistic Δ is
390 shown using a vertical red line. P -value from permutation test.
- 391 h) Slide G1 showing the GIST model-derived immune cell proportions, when the deep learning
392 immune cell type annotation has been used as an informative prior. Solid boxes indicate regions
393 of pathologist's annotated immune spots. Green indicates that immune spots were successfully
394 identified, and red indicates that immune spots were not well captured. The dashed black box,
395 highlighted by the black arrowhead, indicates the same region of interest as in (e), where the false
396 positive immune cell predictions have been mitigated. The green arrowhead highlights a region
397 where the correct identification of a pathologist annotated immune-infiltrated region has
398 improved.
- 399 i) Tissue image showing the region of interest highlighted by a dashed black box in panels (e) and
400 (h). The H&E stain shows minimal evidence of immune infiltration in the areas overlapping the
401 three spatial transcriptomics spots, whose location is shown by black circles.

402 Abbreviations: ST, Spatial Transcriptomics.

403

404 **The GIST model identified large regions of immune cell infiltration that were missed by**
405 **the initial pathologist.**


406 Surprisingly, one of the six breast cancer slides assessed demonstrated a statistically significant
407 decrease in performance when we leveraged the image-derived prior estimates of immune cell
408 infiltration (slide H1 in Fig. 4f, $P = 3.56 \times 10^{-11}$, Supplementary Figure S12g). However, closer
409 inspection of this slide's results revealed that there was a large region of this tumor that was
410 identified as immune cell infiltrated by both the spatial transcriptomics assay and the deep
411 learning model, but this region was not marked by the initial pathologist's annotation

412 (Supplementary Figure S12a-S12e and S12h)). Unsurprisingly, this region was predicted as
413 heavily immune cell infiltrated by the GIST model, which also correctly identified the original
414 pathologist's annotated regions of immune infiltration in this slide (Fig. 5a, Supplementary
415 Figure S12f).

416 Thus, we hypothesized that the apparent decrease in performance may have represented an
417 oversight in the initial pathologist's annotation, and thus a deficiency in the assumed ground
418 truth, rather than a deficiency in the GIST model's prediction. To test this, we devised a
419 procedure that would allow a second independent pathologist (see Author's Contributions) to re-
420 examine the relevant regions of this slide, while remaining blinded to the GIST model's output
421 and the original pathologist's annotation. The second pathologist was presented with ($n = 115$)
422 100×100 -micron subregions from this slide and asked to categorize them as either low, middle,
423 or high levels of immune cell infiltration. These subregions were chosen either from (i) the first
424 pathologist's annotated immune cell regions (ii) high-confidence immune cell regions identified
425 by the GIST model but not the first pathologist or (iii) other randomly chosen regions
426 (representative examples shown in Fig. 5b; see Methods). Remarkably, the second
427 pathologist's reannotation determined no statistical difference between the high-confidence
428 regions of immune cell infiltration annotated by the first pathologist and the additional high-
429 confidence regions identified by the GIST model, which were missed by the first pathologist
430 (Fig. 5c; $P = 0.15$ from Wilcoxon rank-sum test). However, the high-confidence regions of
431 immune cell infiltration identified by GIST were much more likely to be marked as high
432 probability regions of immune cell infiltration when compared to randomly chosen slide regions
433 (Fig. 5c, $P = 3.5 \times 10^{-9}$). Additionally, the second pathologist's high confidence immune
434 infiltrated regions were mirrored by higher estimated proportions by GIST (Fig. 5d). These
435 results support the notion that the additional regions identified by the GIST model were true
436 regions of immune cell infiltration and that the poor performance on this slide arose from an

437 omission in the original pathologist's annotation, not falsely identified regions by the GIST
438 model.

439 We also reexamined the two available spatial transcriptomics slides where the original
440 pathologist's annotation of the H&E images had not identified any regions of immune cell
441 infiltration (Supplementary Figure S13a-b). Surprisingly, for both slides the deep learning model
442 (Fig. 5e, Supplementary Figure 13c) and the expression-only cell type predictions from the
443 spatial transcriptomics assay (Fig. 5f, Supplementary Figure 13d) agreed that there were in fact
444 regions of immune cell infiltration (Fig. 5g, Spearman's correlation = 0.46, $P < 2.2 \times 10^{-16}$;
445 Supplementary Figure 13e, Spearman's correlation = 0.25, $P < 2.2 \times 10^{-4}$). Unsurprisingly, these
446 same regions were identified by the GIST model (Fig. 5h, Supplementary Figure 13f) and thus it
447 seemed plausible that the initial pathologist had also missed these immune infiltrated regions in
448 their initial examination of these two slides. We used the same scoring procedure outlined
449 above to reannotate these slides by the second pathologist, who convincingly annotated these
450 predicted regions as true regions of immune cell infiltration (Figure 5i, $P = 1.5 \times 10^{-9}$;
451 Supplementary Figure 13g, $P = 4.5 \times 10^{-2}$; see Methods), which were also mirrored by higher
452 proportions estimated by GIST (Supplementary Figure 13h-i). Taken together, these results
453 suggest that our GIST model, which can jointly leverage image-derived deep learning
454 predictions with spatial transcriptomics data, has the potential to outperform a human
455 pathologist in identifying predictive and prognostically important features in human tissue
456 sections.



457

458 **Figure 5: GIST model identifies regions of immune cell infiltration that were missed by an initial**
 459 **pathologist's annotation.**

- 460 a) GIST model-derived proportions plotted on top of tissue from slide H1. Green outline indicates
 461 the original annotation of immune infiltrated spot regions identified by the initial pathologist.
 462 b) Three representative 100×100 micron images showing spots from the first pathologist's annotated
 463 regions of immune cell infiltration (top), additional high confidence immune infiltrated regions
 464 identified by the GIST model (middle), and additional randomly selected regions (bottom). Spots
 465 are taken from slide H1.
 466 c) Dot plot showing the second pathologist's immune infiltration grading with a score of low,
 467 middle, and high (y-axis) for spots from different regions of the tissue (x-axis). Spots were taken
 468 from slide H1 from regions previously annotated by the first pathologist as immune-rich,
 469 additional high confidence regions from the GIST model, and additional random regions on the
 470 slide. *P*-values from Wilcoxon rank sum test.

- 471 d) Boxplot showing distribution of GIST model predicted immune cell proportions (y-axis) broken
472 down by immune infiltration grade (x-axis) provided by the second pathologist. For each
473 pathologist grade (low, middle & high), GIST scores are shown for spots from annotated, GIST
474 high confidence, and random regions. Spots taken from slide H1.
- 475 e) Deep learning-derived proportions for spots on slide B1. The color scale shows the predicted
476 proportion of immune cells at a spot.
- 477 f) Gene expression-derived proportions for slide B1 from GIST base-model. The color scale shows
478 the predicted proportion of immune cells at a spot.
- 479 g) Scatter plot showing the per-spot correlation between deep learning-derived predictions (y-axis)
480 and ST gene expression-derived proportions (x-axis) for slide B1. Each dot is a spot and the red
481 line is the regression line. *P*-value from Spearman's correlation test.
- 482 h) GIST model-derived proportions for slide B1. The color scale shows the predicted proportion of
483 immune cells at a spot.
- 484 i) Dot plot showing the second pathologist's immune infiltration grading with a score of low,
485 middle, and high (y-axis) for spots from different regions of the tissue (x-axis). Spots were taken
486 from slide B1 from high confidence regions from the GIST model and random regions on the
487 slide. *P*-value from Wilcoxon rank sum test.

488 In all boxplots, the center line represents the median, bound of box is upper and lower quartiles
489 and the whiskers are $1.5\times$ the interquartile range.

490 Abbreviations: ST, Spatial Transcriptomics.

491

492 **DISCUSSION**

493 We have presented a conceptually novel computational methodology that can leverage data
494 derived from paired tissue images to improve inferences of cell type composition in spatial
495 transcriptomics data. The most exciting application of such a methodology may be the ability to
496 leverage inferences from deep-learning models applied to pathology images, which itself has
497 recently reached close to pathologist level performance in annotating clinically relevant features
498 of tissue sections^{20,21,30}. However, the methodology is highly generalizable and could be easily
499 extended to any image-derived prior information, which we have demonstrated for
500 immunofluorescence. Our proposed integrated approach may have clinical applications in areas
501 of prognostics and diagnostics that rely on cell type information but also has the potential to
502 improve all downstream applications of spatial transcriptomics that rely on accurate cell type
503 annotations, including identification of cell-cell or gene-gene interactions.

504 Our framework will also spur the development of future similar computational approaches.
505 Indeed, any cell type decomposition method that could be re-implemented in a Bayesian
506 framework could be adapted to leverage image-derived prior information and this is likely
507 possible for most of the existing models used in our comparisons-of-methods (Figs. 2 and 3).
508 Thus, there is scope for future model development and optimization within our novel framework.
509 We also anticipate that our framework will lead to new modes of spatial transcriptomics
510 experimental design. For example, we showed that IF data could also be informatively
511 leveraged. This opens the possibility of *a priori* staining for a few particularly informative protein
512 markers, knowing that such markers can be used in downstream analyses to directly influence
513 and improve the results of the spatial transcriptomics data analysis. This may be particularly
514 useful for separating cell types when multicollinearity affects the performance of conventional
515 models for cell type decomposition²².

516 Additionally, while we have shown some illustrative examples, the Bayesian implementation
517 allows enormous flexibility in how prior information is specified. It is theoretically possible to, for
518 example, apply one prior to groups of cell types, or apply multiple partially overlapping priors
519 derived from various sources of information. For the breast cancer dataset shown, we also fixed
520 the λ hyperparameter to 50, using information obtained in the previous dataset. While certainly
521 avoiding overfitting, this is likely a conservative means by which to choose this key value and
522 also assumes that the influence of the image and gene expression data should be treated as
523 equal at each spot—almost certainly an oversimplification. Methods could likely be devised to
524 adaptively adjust the value of the λ hyperparameter, such that, for example, the differences in
525 uncertainty associated with the deep learning-based outputs could be accounted for at each
526 tissue region. Thus, it is likely that creative applications within the described framework will
527 eventually yield improvements over the results presented here.

528 In conclusion, we anticipate that jointly leveraging spatial transcriptomics and pathology images
529 collected from the same tissue section will represent an important conceptually novel
530 computational methodology, which has the potential to improve many applications of emerging
531 spatial transcriptomics technologies, including potential translational applications in clinical and
532 diagnostic pathology.

533

534 **METHODS**

535 **Technical details of the GIST statistical model.**

536 The expression of gene i at each spatial transcriptomics mRNA capture spot j is assumed to be
537 approximately a weighted sum of the average expression of that gene in each of the cell types
538 captured by that spot. If our spatial transcriptomics data are arranged in a matrix Y , where the
539 rows represent $i = 1, \dots, m$ genes and the columns represent $j = 1, \dots, n$ spots, then this
540 relationship can be summarized by the following equation (see also Fig. 2a):

$$541 \quad Y \approx WH$$

542 where W is an $m \times p$ matrix of cell type specific gene expression signatures, approximating the
543 average expression of each gene in each cell type in this tissue, with each column of W
544 representing one of the p cell types and each row representing one of the m genes. H is a
545 $p \times n$ matrix of cell type proportions (or probabilities if the data are subcellular resolution)
546 where each column $H^{(j)}$ represents the proportions of each of p cell types at spot j .

547 Each element of W is best modeled from Ψ (a reference single-cell RNA-seq dataset) using a
548 negative binomial distribution estimated for each gene i , in each cell type k , from the expression
549 data of the available single-cells indexed by l . $\phi_{i,k}$ represents the overdispersion parameter of
550 such a distribution:

$$551 \quad \Psi_{i,k,l} \sim \text{NegativeBinomial}(w_{i,k}, \phi_{i,k})$$

552
$$i = 1, \dots, m; k = 1, \dots, p$$

553 For practical reasons, we approximated the elements of \mathbf{W} by taking the mean normalized
554 (details below) expression of each gene in each cell type in the reference single-cell RNA-seq
555 dataset Ψ .

556 Given \mathbf{Y} and \mathbf{W} , the following model is then used for estimating \mathbf{H} :

557
$$y_{i,j} | \Psi_i, \mathbf{W}_i, \mathbf{H}^{(j)}, v_j, \beta_{0,j}, \sigma_j \sim t(v_j, \beta_{0,j} + \mathbf{W}_i \mathbf{H}^{(j)}, \sigma_j)$$

558
$$i = 1, \dots, m; j = 1, \dots, n; k = 1, \dots, p$$

559 We place a gamma prior (priors are denoted herein by π) on the degrees of freedom parameter
560 v of the t -distribution, using shape and rate parameter values previously proposed by Juarez
561 and Steele³³:

562
$$\pi(v_j) \sim \text{Gamma}(2, 0.1)$$

563
$$v_i > 3$$

564 We constrain the elements of \mathbf{H} to be positive and to sum to one within each spot:

565
$$\sum_{k=1}^p h_{k,j} = 1$$

566
$$h_{k,j} > 0$$

567 This is achieved by placing a non-informative Dirichlet prior on the columns of \mathbf{H} :

568
$$\pi(\mathbf{H}^{(j)}) \sim \text{Dirichlet}(\boldsymbol{\alpha})$$

569
$$\alpha_1 = \alpha_2 = \dots = \alpha_p = 1$$

570 All other parameters are assigned non-informative priors.

571 We use the image data to generate a prior estimate of the abundance of some cell type a (e.g.
572 immune cells) at each spot j (details below), then we place a beta distribution prior on the
573 corresponding proportion of cell type a at spot j :

$$574 \quad \pi(h_{a,j}) \sim \text{Beta}(\tau_j, \lambda)$$

575 Here, τ_j is the mean of the beta distribution representing the image-derived prior estimate for
576 the proportion of this cell type a at spot j . λ is a hyperparameter, representing the total count
577 parameter of the beta distribution, determining how much weight is to be placed on the image
578 data and how much to place on the transcriptomic data.

579 In the notation above, vectors are shown using boldface and matrices bold capital letters. We
580 assume m genes (indexed by i), n spots, (indexed by j), and p cell types (indexed by k).

581

582 **Fitting the GIST and GIST base-model.**

583 The statistical model described above was implemented in the Stan programming language
584 using the *rstan* package. The Hamiltonian Monte Carlo (HMC) algorithm was used to estimate
585 the model parameters. The HMC algorithm was run for 2000 iterations where the first 1000
586 iterations were discarded as burn-in. The posterior mean was used as final parameter
587 estimates.

588

589 **Prior construction.**

590 Mouse brain dataset: To avoid outlier bias in the IF image data the pixel-level image intensity
591 values were first capped at the 99th percentile and values below the 1st percentile were set to
592 zero. These pixel-level intensity values were then rescaled from 0 to 1, by dividing all values by

593 the maximum capped value. Pixels overlapping each spatial transcriptomics mRNA capture spot
594 were defined as those centered around the middle of the spatial transcriptomics spot in a 70-
595 pixel radius—the center of the spot was defined in an annotation file that was output by the 10x
596 Genomics SpaceRanger software. The rescaled pixel-level intensity values were then averaged
597 over the slide regions corresponding to each spatial transcriptomics spot to obtain a single
598 intensity value for each spot. This procedure was repeated for both IF channels—RBFOX3
599 (Neuron) and GFAP (Glia). Finally, the intensity values for each spot in each channel were
600 mapped onto the quantiles of the cell type proportion estimates obtained from a first round of
601 model fitting using the GIST base-model. These IF image-derived mapped spot level intensity
602 values, which act as a proxy for the abundance of neurons or glia, were used as priors on the
603 appropriate parameters in the GIST model.

604 Breast cancer dataset: The deep learning models used in the breast cancer analyses were
605 previously published by Saltz *et al.*³⁰ and were obtained from the Quantitative Imaging in
606 Pathology (QuIP) group's website (https://sbu-bmi.github.io/quip_distro). These are
607 convolutional neural network-based deep learning models, which had been pre-trained to
608 recognize tumor-infiltrating lymphocytes. The original authors had trained these models using
609 pathologist annotated H&E-stained tissues sections from TCGA. We used the VGG16-based
610 model provided by the group. The breast cancer H&E images were converted from JPEG format
611 to tiled TIFF format and the software suite VIPS was used to encode the TIFF files with a micron
612 per pixel (MPP) value for each slide. The encoded TIFF files were processed using QuIP's deep
613 learning pipeline to generate a probability map over the entirety of each breast cancer H&E
614 stained slide image. The deep learning model assigned probability values to patches of 50×50
615 microns. For a given spot, the assigned patch-level probability values were converted to spot-
616 level probability values by taking a weighted sum of the patches, where the weight is the pixel
617 overlap between the patch and the spot. This generated values for each spatial transcriptomics

618 spot that approximately corresponded to the probability of immune cell infiltration. Similarly to
619 the mouse brain IF dataset, these probability values were then mapped onto the distribution of
620 total lymphocyte (T cell and B cell) content estimated from gene expression-derived proportions
621 alone, obtained by an initial round of model fitting using the GIST base-model. These mapped
622 values were used as informative priors on the appropriate model parameters in the GIST model.
623 The image processing code was implemented in Python using imaging libraries PIL.Image and
624 imageio. Visualization and analysis of imaging data were carried out using the NumPy, pandas,
625 and Matplotlib libraries.

626

627 **Quantifying the improvement achieved by the GIST model, compared to an expression-**
628 **only model, by benchmarking against a pathologist-defined ground truth.**

629 For each slide in the breast cancer dataset, we quantified a model's ability to accurately
630 estimate regions of immune cells by the median of immune cell proportions in spots labeled as
631 immune-infiltrated by the original pathologist, divided by the median of immune cell proportions
632 estimated in the other remaining spots:

633
$$Q = \frac{\text{median}(\mathbf{h}_{\text{ImmuneSpots}})}{\text{median}(\mathbf{h}_{\text{OtherSpots}})}$$

634 $\mathbf{h}_{\text{ImmuneSpots}}$ is a vector of model-estimated immune cell proportions for spots annotated by the
635 pathologist as containing immune cells, and $\mathbf{h}_{\text{OtherSpots}}$ are the immune cell proportions
636 estimated at the other spots on the same slide.

637 With better performance, the scalar value Q will increase, as the model's output better matches
638 the pathologist-defined ground truth for this slide. Having defined this performance metric, we
639 defined the improvement of the GIST model over the expression-only GIST base-model below

640 as Δ , a scalar representing the difference between this ratio statistic Q when immune cell
641 proportions were estimated with the GIST model (Q_{GIST}) or the GIST base-model
642 ($Q_{GISTBaseModel}$):

$$643 \quad \Delta = Q_{GIST} - Q_{GISTBaseModel}$$

644 To assess whether the improved performance Δ observed for the GIST model over the GIST
645 base-model was statistically significant, we used a permutation-based strategy, building a null
646 distribution by randomly shuffling the pathologist's spot level annotations. Specifically, for each
647 permutation, the spots were randomly assigned as either immune infiltrated or non-immune,
648 fixing the total number of immune infiltrated spots to the same number as the pathologist's
649 annotation of that slide; we then computed the improvement in the performance Δ_{perm} of the
650 GIST model over the GIST base-model using the same procedure that was applied to the real
651 arrangement of the pathologist's annotations. This was repeated for 100,000 permutations,
652 generating a null distribution against which to compare the observed test statistic Δ . A P -value
653 was then calculated by the proportion of permuted values Δ_{perm} that achieved a value at least
654 as extreme as Δ , the test statistic observed in the pathologist's real annotations. In the cases
655 where no permuted value more extreme than the original test statistic was observed (G1 and
656 H1), a P -value was calculated by approximating the null distribution using a normal distribution,
657 with a mean and standard deviation equal to that of the Δ_{perm} values from the 100,000
658 permutations.

659

660 **Second pathologist's re-annotation of the breast cancer spatial transcriptomics slides.**

661 A second pathologist was asked to assign new immune infiltration grades from H&E images of
662 spots for three spatial transcriptomics breast cancer slides – B1, C1, and H1. The pathologist
663 (co-author Dr. Heather Tillman) was asked to *blindly* score H&E images of slide regions

664 overlapping the spatial transcriptomics mRNA capture spots from three groups of spots: These
665 were (i) spots that were annotated as immune cell infiltrated by the original pathologist (slide H1
666 only), (ii) spots that were identified as high-confidence immune infiltrated by the GIST model, or
667 (iii) other randomly chosen spots. High-confidence immune-cell-infiltrated spots from the GIST
668 model were selected as the spots having a predicted proportion of immune cells that was
669 greater than the upper quartile plus 1.5 times the interquartile range of the data, a *de facto*
670 metric used to define outliers. For each slide, the number of random spots selected was equal
671 to the number of spots included from the GIST model. This second pathologist was then asked
672 to score/grade an H&E stain image of each spot, scoring immune cell infiltration levels as low,
673 middle, or high, while remaining blinded to the group from which the spot image was selected.
674 This provided a new score for each spot from each of the three groups (annotated, GIST,
675 random). We then applied a one-sided Wilcoxon rank-sum test to assess whether these scores
676 were significantly higher in the group of spots predicted as high confidence immune infiltrated by
677 the GIST model compared to the randomly selected spots or the immune infiltrated spots from
678 the initial pathologist's annotation, where low, middle and high scores were encoded on an
679 ordinal scale as 1, 2 and 3 respectively.

680

681 **Simulations to assess the ability of the GIST base-model to accurately identify cell type**
682 **composition in gene expression data from a mixture of cell types.**

683 Splatter

684 The accuracy of cell type proportions estimated from the various computational methods was
685 compared to the GIST base-model by first creating synthetic mixtures of gene expression data
686 using the popular Splatter model²⁵. We used the Splatter model with a slight modification, which
687 was recently proposed by Zhang *et al.*³⁴, who reported that the native Splatter model did not

688 capture the empirical distribution of log fold changes observed in real data. The enhanced
689 Splatter model was obtained from the GitHub repository of Zhang *et al.*
690 (<https://github.com/Irrationone/splatter>), where the author's had learned the simulation
691 parameters from the counts matrix of a publicly available PBMC single-cell RNA-seq dataset
692 generated by 10X Genomics. The parameters for log fold changes were learned by fitting a
693 truncated student's t-distribution to the log fold changes between B cells and CD4 T cells in this
694 same PBMC dataset.

695 Using the enhanced Splatter framework, we generated a dataset with 100 gene expression
696 samples, each created from mixtures of cell types, along with a simulated paired reference
697 single-cell RNA-seq dataset. The paired single-cell RNA-seq data were collapsed by their mean
698 to create the required reference signature matrix W , which was passed to each of the
699 computational methods. Each expression mixture sample was generated by taking a weighted
700 average of gene expression across 100 cells (generated independently of the reference single-
701 cell RNA-seq data) from each of six synthetic cell types. Ground truth cell type proportions for
702 the 100 simulated mixture samples were randomly generated from a Dirichlet distribution, where
703 each cell type was assigned equal weight.

704

705 Immune cell deconvolution.

706 We performed a second set of benchmarking simulations using the framework developed by
707 Strum *et al.*²⁶, which rather than relying entirely on simulation, created a mixture gene
708 expression dataset by computationally mixing real single-cell RNA-seq data, previously
709 generated by Schelker *et al.*³⁵. In this benchmark, ground truth was established by mixing gene
710 expression counts from 500 single-cells from each of eight immune cell types in known
711 proportions and the simulated mixture was created by taking an average across cells. For the

712 fairest comparison, we supplied each of the methods the LM22 cell type signature matrix³⁶
713 (corresponding to W in our notation herein), which is a signature matrix created by the
714 developers of CIBERSORT that represents average gene expression values in each of 22
715 immune cell types. Note this was not possible for Stereoscope, which only accepts single-cell
716 RNA-seq data as the reference input, from which it estimates the cell type signature matrix
717 internally. Because the LM22 cell types do not have a strict one-to-one correspondence with the
718 cell types annotated in Schelker *et al.*, the results were mapped to the most relevant cell type
719 using the same mappings previously employed by Strum *et al.*

720 In all simulations, the performance of each method was summarized by the mean absolute error
721 (MAE), which is the average of the absolute value of the difference between each predicted cell
722 type proportion and the known simulated ground truth proportion:

$$723 \quad \text{MAE} = \frac{\sum_{i=1}^n |y_i - x_i|}{n} = \frac{\sum_{i=1}^n |e_i|}{n}$$

724 Where y_i is a predicted cell type proportion, x_i is a predicted proportion, e_i is the error
725 associated with the prediction, and n is the total number of predicted data points generated by a
726 given method.

727

728 **Datasets used in the analyses.**

729 Mouse Brain

730 The mouse brain spatial transcriptomics Visium data with associated IF images were
731 downloaded from the 10X Genomics website: [https://support.10xgenomics.com/spatial-gene-](https://support.10xgenomics.com/spatial-gene-expression/datasets/1.1.0/V1_Adult_Mouse_Brain_Coronal_Section_2)
732 [expression/datasets/1.1.0/V1_Adult_Mouse_Brain_Coronal_Section_2](https://support.10xgenomics.com/spatial-gene-expression/datasets/1.1.0/V1_Adult_Mouse_Brain_Coronal_Section_2)

733 As a cell type reference W for these data, we used the curated mouse brain single-cell RNA-seq
734 data provided by Andersson *et al.*¹⁸. This data had been originally retrieved from
735 <http://www.mousebrain.org> and was processed by Andersson *et al.* for use in spatial
736 transcriptomics analysis: <https://github.com/almaan/stereoscope/tree/master/data/mousebrain>

737

738 Breast Cancer

739 The eight separate breast cancer spatial transcriptomics slides, previously generated by
740 Andersson *et al.*, were downloaded from <https://github.com/almaan/her2st>. This repository
741 contained count matrices generated from the spatial transcriptomics assays, H&E images of the
742 tissue sections (with and without pathologist annotation), and matrices detailing the location of
743 the spots.

744 The single-cell RNA-seq breast cancer dataset, used to generate the cell type reference matrix
745 W for all breast cancer analyses, was previously generated by Karaayvaz *et al.*³⁷ and obtained
746 from: https://github.com/Michorlab/tnbc_scrnaseq.

747

748 **Data preprocessing, filtering, normalization and imputation.**

749 All public datasets were obtained as preprocessed counts matrices, which had been processed
750 according to the previous authors. Generally, spatial transcriptomics data displayed greater
751 sparsity than the single-cell RNA-seq data, which arises because of differences in platform-
752 specific mRNA capture efficiency. To alleviate this difference, we used a non-parametric
753 imputation approach. Specifically, we used the `knnSmooth`³⁸ algorithm (available at the GitHub
754 repository <https://github.com/yanailab/knn-smoothing>) to impute the spatial transcriptomics data.

755 For the IF mouse brain dataset, we set the “number of nearest neighbors to aggregate”
756 parameter k to 5 and the “number of principal components” parameter d to 10 (author’s
757 suggested default). For the breast cancer dataset, we used the same approach with slight
758 modifications. The resolution of spots on the breast cancer slides was coarser than on the
759 Visium array and transcript capture was poorer. Thus, to overcome these limitations, we
760 combined the spots from all the breast cancer spatial transcriptomics slides and imputed them
761 together using the knnSmooth algorithm with a k parameter of 10, mitigating the lower transcript
762 capture efficiency in the breast cancer dataset.

763 Thereafter, both the spatial transcriptomics and single-cell RNA-seq data were normalized
764 separately by using Seurat’s SCTransform³⁹, which importantly removes technical effects such
765 as library size effects. We restricted the single-cell RNA-seq and spatial transcriptomics data to
766 the intersection of their 2,000 most highly variable genes, yielding totals of 1,024 and 837 genes
767 used for GIST model fitting in the mouse and breast cancer datasets respectively.

768

769 **Software and code availability.**

770 The GIST model has been made available as an R package, which can be obtained at:

771 <https://github.com/asifzubair/GIST>

772 All the code for the analyses presented in this manuscript are available on GitHub:

773 <https://github.com/asifzubair/GIST-paper>

774 Note: These are private repositories accessible by the links above for peer review, these
775 repositories will be made publicly accessible upon completion of manuscript review.

776

777

778 **Author Contributions.**

779 P.G. conceived and directed the project. A.Z. and P.G. wrote the code, with additional input
780 from R.C. P.G. and A.Z wrote the manuscript. H.T. blindly re-annotated the breast cancer
781 pathology slides to resolve the discrepancies between the GIST model and the original
782 pathologist's annotations. S.N., W.C.W, M.P., H.M.L, and J.E. provided additional support in
783 data analysis and interpretation. All author's edited and approved the final manuscript.

784

785 **Acknowledgements.**

786 PG is supported by an NIGMS R35 award (R35GM138293) an R01 grant from NCI
787 (R01CA260060), and a K99/R00 (R00HG009679) from NHGRI. PG also receives support from
788 ALSAC.

789 **References.**

- 790 1 Peck, M., Moffat, D., Latham, B. & Badrick, T. Review of diagnostic error in anatomical pathology
791 and the role and value of second opinions in error prevention. *Journal of clinical pathology* **71**,
792 995-1000 (2018).
- 793 2 Vickovic, S. *et al.* High-definition spatial transcriptomics for in situ tissue profiling. *Nature*
794 *methods* **16**, 987-990 (2019).
- 795 3 Stickels, R. R. *et al.* Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-
796 seqV2. *Nature biotechnology* **39**, 313-319 (2021).
- 797 4 Rodriques, S. G. *et al.* Slide-seq: A scalable technology for measuring genome-wide expression at
798 high spatial resolution. *Science* **363**, 1463-1467 (2019).
- 799 5 Liu, Y. *et al.* High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue.
800 *Cell* **183**, 1665-1681. e1618 (2020).
- 801 6 Chen, A. *et al.* Large field of view-spatially resolved transcriptomics at nanoscale resolution.
802 *bioRxiv* (2021).
- 803 7 Van de Velde, L.-A. *et al.* Neuroblastoma formation requires unconventional CD4 T cells and
804 myeloid amino acid metabolism. *bioRxiv* (2021).
- 805 8 Moncada, R. *et al.* Integrating microarray-based spatial transcriptomics and single-cell RNA-seq
806 reveals tissue architecture in pancreatic ductal adenocarcinomas. *Nature biotechnology* **38**, 333-
807 342 (2020).
- 808 9 Svensson, V., Teichmann, S. A. & Stegle, O. SpatialDE: identification of spatially variable genes.
809 *Nature methods* **15**, 343-346 (2018).
- 810 10 Sun, S., Zhu, J. & Zhou, X. Statistical analysis of spatial expression patterns for spatially resolved
811 transcriptomic studies. *Nature methods* **17**, 193-200 (2020).
- 812 11 Pham, D. T. *et al.* stLearn: integrating spatial location, tissue morphology and gene expression to
813 find cell types, cell-cell interactions and spatial trajectories within undissociated tissues. *bioRxiv*
814 (2020).
- 815 12 Maaskola, J. *et al.* Charting tissue expression anatomy by spatial transcriptome decomposition.
816 *BioRxiv*, 362624 (2018).
- 817 13 Tanevski, J., Gabor, A., Flores, R. O. R., Schapiro, D. & Saez-Rodriguez, J. Explainable multi-view
818 framework for dissecting inter-cellular signaling from highly multiplexed spatial data. *BioRxiv*
819 (2020).
- 820 14 Arnol, D., Schapiro, D., Bodenmiller, B., Saez-Rodriguez, J. & Stegle, O. Modeling cell-cell
821 interactions from spatial molecular data with spatial variance component analysis. *Cell reports*
822 **29**, 202-211. e206 (2019).
- 823 15 Elosua-Bayes, M., Nieto, P., Mereu, E., Gut, I. & Heyn, H. SPOTlight: seeded NMF regression to
824 deconvolute spatial transcriptomics spots with single-cell transcriptomes. *Nucleic acids research*
825 **49**, e50-e50 (2021).
- 826 16 Cable, D. M. *et al.* Robust decomposition of cell type mixtures in spatial transcriptomics. *Nature*
827 *Biotechnology*, 1-10 (2021).
- 828 17 Biancalani, T. *et al.* Deep learning and alignment of spatially-resolved whole transcriptomes of
829 single cells in the mouse brain with Tangram. *bioRxiv* (2020).
- 830 18 Andersson, A. *et al.* Single-cell and spatial transcriptomics enables probabilistic inference of cell
831 type topography. *Communications biology* **3**, 1-8 (2020).
- 832 19 van der Laak, J., Litjens, G. & Ciampi, F. Deep learning in histopathology: the path to the clinic.
833 *Nature medicine* **27**, 775-784 (2021).
- 834 20 Kather, J. N. *et al.* Pan-cancer image-based detection of clinically actionable genetic alterations.
835 *Nature Cancer* **1**, 789-799 (2020).

- 836 21 Fu, Y. *et al.* Pan-cancer computational histopathology reveals mutations, tumor composition and
837 prognosis. *Nature Cancer* **1**, 800-810 (2020).
- 838 22 Li, B., Liu, J. S. & Liu, X. S. Revisit linear regression-based deconvolution methods for tumor gene
839 expression data. *Genome biology* **18**, 1-5 (2017).
- 840 23 Stenzinger, A. *et al.* in *Seminars in cancer biology*. (Elsevier).
- 841 24 Haibe-Kains, B. *et al.* Transparency and reproducibility in artificial intelligence. *Nature* **586**, E14-
842 E16 (2020).
- 843 25 Zappia, L., Phipson, B. & Oshlack, A. Splatter: simulation of single-cell RNA sequencing data.
844 *Genome biology* **18**, 1-15 (2017).
- 845 26 Sturm, G. *et al.* Comprehensive evaluation of transcriptome-based cell-type quantification
846 methods for immuno-oncology. *Bioinformatics* **35**, i436-i445 (2019).
- 847 27 Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. in *Cancer systems*
848 *biology* 243-259 (Springer, 2018).
- 849 28 Gong, T. & Szustakowski, J. D. DeconRNASeq: a statistical framework for deconvolution of
850 heterogeneous tissue samples based on mRNA-Seq data. *Bioinformatics* **29**, 1083-1085 (2013).
- 851 29 Kleshchevnikov, V. *et al.* Comprehensive mapping of tissue cell architecture via integrated single
852 cell and spatial transcriptomics. *bioRxiv* (2020).
- 853 30 Saltz, J. *et al.* Spatial organization and molecular correlation of tumor-infiltrating lymphocytes
854 using deep learning on pathology images. *Cell reports* **23**, 181-193. e187 (2018).
- 855 31 Jochems, C. & Schlom, J. Tumor-infiltrating immune cells and prognosis: the potential link
856 between conventional cancer therapy and immunity. *Experimental biology and medicine* **236**,
857 567-579 (2011).
- 858 32 Taube, J. M. *et al.* Association of PD-1, PD-1 ligands, and other features of the tumor immune
859 microenvironment with response to anti-PD-1 therapy. *Clinical cancer research* **20**, 5064-5074
860 (2014).
- 861 33 Juárez, M. A. & Steel, M. F. Model-based clustering of non-Gaussian panel data based on skew-t
862 distributions. *Journal of Business & Economic Statistics* **28**, 52-66 (2010).
- 863 34 Zhang, A. W. *et al.* Probabilistic cell-type assignment of single-cell RNA-seq for tumor
864 microenvironment profiling. *Nature methods* **16**, 1007-1015 (2019).
- 865 35 Schelker, M. *et al.* Estimation of immune cell content in tumour tissue using single-cell RNA-seq
866 data. *Nature communications* **8**, 1-12 (2017).
- 867 36 Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles. *Nature*
868 *methods* **12**, 453-457 (2015).
- 869 37 Karaayvaz, M. *et al.* Unravelling subclonal heterogeneity and aggressive disease states in TNBC
870 through single-cell RNA-seq. *Nature communications* **9**, 1-10 (2018).
- 871 38 Wagner, F., Yan, Y. & Yanai, I. K-nearest neighbor smoothing for high-throughput single-cell
872 RNA-Seq data. *BioRxiv*, 217737 (2018).
- 873 39 Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data
874 using regularized negative binomial regression. *Genome biology* **20**, 1-15 (2019).

875